Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $32,542.65 in Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 10,331 shares of Checkpoint Therapeutics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total transaction of $32,542.65. Following the transaction, the chief executive officer now directly owns 3,775,019 shares of the company’s stock, valued at approximately $11,891,309.85. This trade represents a 0.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Checkpoint Therapeutics Stock Performance

Shares of NASDAQ CKPT opened at $3.46 on Friday. The firm has a market cap of $168.95 million, a PE ratio of -1.88 and a beta of 1.36. The firm has a fifty day moving average of $3.36 and a 200 day moving average of $3.00. Checkpoint Therapeutics, Inc. has a one year low of $1.38 and a one year high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). On average, equities analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Checkpoint Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its holdings in Checkpoint Therapeutics by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 445,111 shares of the company’s stock worth $1,425,000 after acquiring an additional 17,460 shares in the last quarter. HB Wealth Management LLC increased its holdings in Checkpoint Therapeutics by 96.9% in the 4th quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock worth $513,000 after acquiring an additional 75,560 shares in the last quarter. PVG Asset Management Corp increased its holdings in Checkpoint Therapeutics by 9.2% in the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock worth $336,000 after acquiring an additional 12,676 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Checkpoint Therapeutics by 160.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after purchasing an additional 80,000 shares during the last quarter. Finally, State Street Corp boosted its stake in Checkpoint Therapeutics by 32.2% during the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock worth $212,000 after purchasing an additional 23,000 shares during the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. D. Boral Capital assumed coverage on shares of Checkpoint Therapeutics in a report on Monday, January 13th. They set a “buy” rating and a $9.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a report on Monday, December 16th. Finally, Lake Street Capital lifted their target price on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a report on Monday, December 16th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.